Literature DB >> 19804415

LRRK2 in Parkinson's disease: function in cells and neurodegeneration.

Philip J Webber1, Andrew B West.   

Abstract

The detailed characterization of the function of leucine-rich repeat kinase 2 (LRRK2) may provide insight into the molecular basis of neurodegeneration in Parkinson's disease (PD) because mutations in LRRK2 cause a phenotype with strong overlap to typical late-onset disease and LRRK2 mutations are responsible for significant proportions of PD in some populations. The complexity of large multidomain protein kinases such as LRRK2 challenges traditional functional approaches, although initial studies have successfully defined the basic mechanisms of enzyme activity with respect to the putative effects of pathogenic mutations on kinase activity. The role of LRRK2 in cells remains elusive, with potential function in mitogen-activated protein kinase pathways, protein translation control, programmed cell death pathways and activity in cytoskeleton dynamics. The initial focus on LRRK2-kinase-dependent phenomena places emphasis on the discovery of LRRK2 kinase substrates, although candidate substrates are so far confined to in vitro assays. Here, hypothetical mechanisms for LRRK2-mediated cell death and kinase activation are proposed. As a promising target for neuroprotection strategies in PD, in vitro and in vivo models that accurately demonstrate LRRK2's function relevant to neurodegeneration will aide in the identification of molecules with the highest chance of success in the clinic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804415      PMCID: PMC3700730          DOI: 10.1111/j.1742-4658.2009.07342.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  57 in total

1.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors:  Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal:  Cell       Date:  2004-03-19       Impact factor: 41.582

Review 2.  Coordinating ERK/MAPK signalling through scaffolds and inhibitors.

Authors:  Walter Kolch
Journal:  Nat Rev Mol Cell Biol       Date:  2005-11       Impact factor: 94.444

3.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.

Authors:  Christian Johannes Gloeckner; Norbert Kinkl; Annette Schumacher; Ralf J Braun; Eric O'Neill; Thomas Meitinger; Walter Kolch; Holger Prokisch; Marius Ueffing
Journal:  Hum Mol Genet       Date:  2005-12-01       Impact factor: 6.150

4.  Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.

Authors:  Silvy da Rocha Dias; Frank Friedlos; Yvonne Light; Caroline Springer; Paul Workman; Richard Marais
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

5.  The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1.

Authors:  A Rana; K Gallo; P Godowski; S Hirai; S Ohno; L Zon; J M Kyriakis; J Avruch
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

6.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

Authors:  Andrew B West; Darren J Moore; Saskia Biskup; Artem Bugayenko; Wanli W Smith; Christopher A Ross; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

7.  Two CD95 (APO-1/Fas) signaling pathways.

Authors:  C Scaffidi; S Fulda; A Srinivasan; C Friesen; F Li; K J Tomaselli; K M Debatin; P H Krammer; M E Peter
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

8.  Oligomerization-induced differential dephosphorylation of c-Met receptor tyrosine kinase.

Authors:  Payal R Sheth; Stanley J Watowich
Journal:  Biochemistry       Date:  2005-08-23       Impact factor: 3.162

9.  Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3.

Authors:  I W Leung; N Lassam
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

10.  Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures.

Authors:  N Oshiro; Y Fukata; K Kaibuchi
Journal:  J Biol Chem       Date:  1998-12-25       Impact factor: 5.157

View more
  14 in total

1.  LRRK2 function on actin and microtubule dynamics in Parkinson disease.

Authors:  Loukia Parisiadou; Huaibin Cai
Journal:  Commun Integr Biol       Date:  2010-09

Review 2.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

3.  The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.

Authors:  Jason P Covy; Benoit I Giasson
Journal:  J Neurochem       Date:  2010-08-19       Impact factor: 5.372

4.  Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.

Authors:  Philip J Webber; Archer D Smith; Saurabh Sen; Matthew B Renfrow; James A Mobley; Andrew B West
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

Review 5.  Receptor-interacting protein (RIP) kinase family.

Authors:  Duanwu Zhang; Juan Lin; Jiahuai Han
Journal:  Cell Mol Immunol       Date:  2010-04-12       Impact factor: 11.530

6.  Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.

Authors:  Xiaodong Ding; Sandeep K Barodia; Lisha Ma; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2016-11-24       Impact factor: 5.996

7.  Structural and functional in silico analysis of LRRK2 missense substitutions.

Authors:  Fernando Cardona; Marta Tormos-Pérez; Jordi Pérez-Tur
Journal:  Mol Biol Rep       Date:  2014-02-02       Impact factor: 2.316

8.  The impact of genetic research on our understanding of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

9.  ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2.

Authors:  Karina Haebig; Christian Johannes Gloeckner; Marta Garcia Miralles; Frank Gillardon; Claudia Schulte; Olaf Riess; Marius Ueffing; Saskia Biskup; Michael Bonin
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.

Authors:  Tatsunori Maekawa; Sayuri Mori; Yui Sasaki; Takashi Miyajima; Sadahiro Azuma; Etsuro Ohta; Fumiya Obata
Journal:  Mol Neurodegener       Date:  2012-04-25       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.